Capricor Therapeutics Faces Legal Challenge as Key Drug Trial Nears Completion
Published on 10/30/2025 at 11:25 | Redaktion boerse-global.de
Capricor Therapeutics finds itself navigating turbulent waters as a federal securities class action lawsuit casts uncertainty over the company’s future. The legal investigation, made public on October 28, 2025, emerges at what could be the most crucial moment for the biotechnology firm’s flagship treatment targeting Duchenne muscular dystrophy.
Kuehn Law has initiated legal proceedings in federal court, focusing on whether Capricor’s leadership may have breached fiduciary responsibilities. Central to the case are allegations that company insiders potentially provided investors with material information about the cell therapy Deramiocel while possibly disseminating inaccurate or misleading statements regarding four-year data from the Phase 2 HOPE-2 clinical study.
The litigation’s outcome Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
